Home / Business and Economy / Moderna Settles Patent Dispute, Eyes Cancer Vaccines
Moderna Settles Patent Dispute, Eyes Cancer Vaccines
4 Mar
Summary
- Moderna resolves a long-standing legal dispute over COVID-19 vaccine technology.
- The company will pay up to $2.25 billion to settle lawsuits with Genevant and Arbutus.
- This settlement allows Moderna to refocus on its promising cancer vaccine pipeline.
Moderna's stock experienced a notable 9% increase on Wednesday, largely attributed to the resolution of a long-standing legal dispute over the lipid nanoparticle technology essential for its COVID-19 vaccine.
The settlement involves payments potentially reaching $2.25 billion to Genevant, a subsidiary of Roivant Sciences, and Arbutus Biopharma. This agreement effectively concludes all U.S. and international legal actions that accused Moderna of unauthorized use of patented technology.
This legal certainty is anticipated to redirect investor attention towards Moderna's pipeline, particularly its cancer vaccines under development. Analysts highlighted that the company is now positioned to concentrate on upcoming oncology readouts scheduled for 2026, which are viewed as significant future growth drivers.
Moderna's financial commitments include an upfront payment of $950 million in July 2026, with an additional $1.3 billion contingent on the outcome of a separate legal appeal. Crucially, the company will not owe future royalties for the technology, representing a considerable success in the negotiations.
While the payment is less than some analysts had feared, it could reduce Moderna's cash reserves by 2026. The company's management also faces ongoing uncertainty regarding its separate lawsuit against Pfizer and BioNTech concerning mRNA technology patents.
